Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKC\(\varepsilon\) pathway in dorsal root ganglion neurons

Hai-Li Pan, Yu-Qiu Zhang, Zhi-Qi Zhao*

**Abstract**

**Background:** It has been demonstrated that lysophosphatidic acid (LPA) released from injury tissue and transient receptor potential vanilloid 1 (TRPV1) receptor are implicated in the induction of chronic pain. In the present study we examined whether an interaction between LPA receptor LPA\(_1\) and TRPV1 in dorsal root ganglion (DRG) neurons contributes to the development of bone cancer pain.

**Results:** Bone cancer was established by injection of mammary gland carcinoma cells into the rat tibia. Following the development of bone cancer pain, the TRPV1 expression and capsaicin-evoked currents were up-regulated in rat DRG neurons at L\(_4-6\) segments. Immunohistochemistry staining revealed a high co-localization of LPA\(_1\) with TRPV1 in DRG neurons. In isolated DRG neurons, whole-cell patch recording showed that capsaicin-induced currents were potentiated by LPA in a dose-dependent manner. The potentiation was blocked by either LPA\(_1\) antagonist, protein kinase C (PKC) inhibitor or PKC\(\varepsilon\) inhibitor, but not by protein kinase A (PKA) inhibitor or Rho inhibitor. In the behavioral tests, both mechanical allodynia and thermal hyperalgesia in bone cancer rats were attenuated by LPA\(_1\) antagonist.

**Conclusion:** LPA potentiates TRPV1 current via a PKC\(\varepsilon\)-dependent pathway in DRG neurons of rats with bone cancer, which may be a novel peripheral mechanism underlying the induction of bone cancer pain.

**Background**

Pain is the first clinical symptom of cancer in a large population of cancer patients, particularly in advanced or terminal cancer patients [1], which strongly impacts the patients’ quality of life. Tumor-derived, inflammatory, and neuropathic factors may simultaneously contribute to cancer pain such as bone cancer pain [2].

Lysophosphatidic acid (LPA) is a lipid metabolite released after tissue injury, which induces diverse cellular responses including proliferation, adhesion, migration, morphogenesis, differentiation and survival [3]. Increasing evidence shows that LPA is a key mediator in cancer development including cancer cell proliferation, survival and migration [4-7]. There is a high concentration of LPA in ascitic fluid and plasma of cancer patients. Released by activated blood platelets [8], LPA promotes progression of bone metastases by inducing secretion of tumor-derived cytokine (IL-6 and IL-8) in breast and ovarian cancer cells [9,10]. Additionally, lines of study have revealed that LPA may also be a crucial factor in the initiation of neuropathic pain mediated by demyelination of peripheral nerves via activation of LPA receptor [11,12]. Six subtypes of LPA receptor, LPA\(_1-6\), are all G protein-coupled receptors. Three endothelial differentiation gene (EDG) family of G-protein-coupled receptors, EDG-2, EDG-4 and EDG-7 were identified as LPA receptors successively, and were named LPA\(_1-3\) respectively. Then p2y9 or GPR23, GPR92 and GPR87 were also identified as LPA receptors, named as LPA\(_4-6\) respectively [3,13,14]. Among the six subtypes, LPA\(_1\) receptor is the main subtype expressed in dorsal root ganglion (DRG) [11]. LPA\(_1\) is capable of interacting with three major G protein families, the G\(_i\), G\(_o\), and G\(_{12}\) family, resulting in the activation of their downstream cascades: mitogen-activated protein kinase (MAPK), protein kinase C (PKC) and Rho (a small GTP-binding protein).
protein)-Rho kinase, while inhibiting protein kinase A (PKA) pathway [3]. Several studies have demonstrated that LPA$_1$ participates in the development of neuropathic pain through the Rho pathway [11,15,16].

In patients with advanced cancers such as breast, lung, prostate or myeloma cancer, bone pain is the most frequent cancer-induced chronic pain. However, the mechanisms underlying the development of bone pain are not completely understood. Bone cancer induces mechanical bone deformation and local tissue acidosis which may activate nociceptors via multiple molecular mechanisms, particularly by activation of the capsaicin receptor, transient receptor potential vanilloid (TRPV1). Compelling evidence has testified that TRPV1 is a critical signal molecule in the development of physiological and pathological pain [17]. It has been shown that TRPV1 is involved in the induction of bone cancer pain [18-22] and is activated by direct phosphorylation via PKC pathway [23-26], particularly via PKCε [27].

In the last decade, bone cancer pain models have been successfully established and used to explore associated mechanisms [28-30]. Given expression of LPA$_1$ and TRPV1 in the DRG neurons, the present study focused on whether LPA$_1$ is involved in bone cancer pain via cross-talk with TRPV1 and the possible signal pathways in the peripheral mechanism underlying bone cancer pain.

**Results**

**Bone cancer-induced increase in expression of TRPV1 and capsaicin-induced currents in rat DRGs**

To elucidate the role of TRPV1 in bone cancer pain, we examined TRPV1 levels in the DRG at the L4-6 spinal segments 14 days after cancer cell implantation. Western blotting results showed that ipsilateral expression of TRPV1 in DRGs was higher in cancer rats (n = 6) than in sham rats (n = 6). The expression of TRPV1 was elevated by 53% ± 0.07 in the ipsilateral DRGs (DRGs from cancer rats (TRPV1/Tubulin)/from sham rats (TRPV1/Tubulin) = 1.53 ± 0.07, p < 0.01) (Figure 1A and 1B).

Capsaicin-evoked inward currents were recorded in L4-6 DRG neurons of sham-operated rats and bone cancer rats 14-16 days after inoculation. A low concentration of capsaicin was used to minimize desensitization of TRPV1. Given that repetitive administration of 500 nM capsaicin (3 s per minute four times) failed to induce detectable desensitization of TRPV1 currents [27], this concentration was used in the following tests. The percentage of DRG neurons responsive to capsaicin (0.5 μM) were divided into the low current amplitude group and the high current amplitude group according to the amplitude of TRPV1 currents. In the former (Figure 1C), the average amplitude of TRPV1 currents in cancer rats (56.3 ± 9.41 pA, n = 14) was higher than that in sham-operated rats (29.3 ± 6.14 pA, n = 15, p < 0.05). Similar results were obtained in the high current amplitude group (Figure 1D). TRPV1 currents were higher in cancer rats (453.3 ± 79.48 pA, n = 14) than that in sham-operated rats (253.6 ± 28.45 pA, n = 15, p < 0.05). These results suggested that neurons in bone cancer rats were more sensitive to capsaicin.

**Co-localization of TRPV1 and LPA$_1$ receptor in DRG neurons**

To investigate the possible cross-talk between TRPV1 and LPA$_1$, double immunolabeling of the TRPV1 and LPA$_1$ receptor (EDG-2) was detected in the DRG neurons. As shown in Figure 2 a large population of DRG neurons expressed TRPV1 (red) and EDG-2 (green). TRPV1 and EDG-2 were widely co-expressed in DRG neurons (orange). Co-localization of TRPV1 and EDG-2 in a same neuron provides the basis for their cross-talk.

**Potentiation of TRPV1 current by LPA in isolated DRG neurons**

TRPV1 currents were found to be potentiated by LPA perfusion (Figure 3), while totally blocked by 10 μM capsazepine (cpz), the antagonist of TRPV1, even after LPA perfusion (inserted figure in Figure 3A). LPA-induced potentiation was found in a dose-dependent manner (Figure 3D). After 1 μM, 0.1 μM or 0.01 μM LPA was perfused, TRPV1 currents were increased by 221% ± 0.37 (p < 0.001) in 8 out of 11 cells, 109% ± 0.19 (p < 0.001) in 6 out of 9 cells and 58% ± 0.09 (p < 0.001) in 18 out of 26 cells recorded, respectively. The currents were maximal at 3 min after LPA perfusion under all of the three concentrations. No obvious potentiation of the current by 0.001 μM LPA (n = 15) was observed (data not shown). To minimize the pharmacological effect of LPA, 0.01 μM LPA was used in the later experiments.

Furthermore, potentiation of TRPV1 by LPA was examined in the bone cancer state. 0.01 μM LPA couldn’t potentiate the TRPV1 current induced by 0.5 μM capsaicin in all of the DRG neurons (n = 24) in bone cancer rats. To avoid the possible ceiling effect, a lower concentration of capsaicin (0.05 μM) was then used. LPA (0.01 μM) could potentiate the TRPV1 current induced by 0.05 μM capsaicin in 31.58% (n = 19) DRG neurons of sham rats and 60% (n = 19) cells in cancer rats. A very low concentration of capsaicin (0.5 nM) failed to evoke TRPV1 currents in all of the DRG neurons.
neurons tested (n = 11) in sham-operated rats, whereas 40% of the DRG neurons tested (n = 20) were responsive to capsaicin in bone cancer rats. We examined the effect of LPA on 12 neurons which did not respond to 0.5 nM capsaicin (sub-threshold concentration) in bone cancer rats. As shown in Figure 4A, capsaicin could evoke a TRPV1 current (the lower trace) in 8 out of 12 neurons after perfusion of LPA (0.01 μM), indicating LPA-induced potentiation of TRPV1 currents under bone cancer state. However, this phenomenon was not observed in sham-operated rats (Figure 4B, n = 11).

**Figure 1** Up-regulation of TRPV1 expression and enhancement of capsaicin-induced currents in DRG neurons of cancer rats. Compared with sham rats, TRPV1 expression was increased in ipsilateral DRGs at L4-L6 of bone cancer rats (A and B). C: In the low current amplitude group, TRPV1 currents of DRG neurons in bone cancer rats were higher than that in sham-operated rats. D: In the high current amplitude group, a similar result as (C) was obtained. Inserted figures in (C and D) represent typical currents recorded in the low and high current groups, respectively.
PKC, particularly PKCα, but not PKA or Rho, mediates LPA-induced potentiation of TRPV1 currents.

Among the six LPA receptors, LPA1, LPA2, LPA3, LPA4, LPA5, and LPA6, LPA1 receptor is the main subtype expressed in the DRG neurons [11]. LPA failed to potentiate TRPV1 currents in all of the neurons tested after incubated with LPA1 antagonist VPC32183 for 30 min (n = 15) (Figure 5A, F, p < 0.05), suggesting that activation of LPA1 receptor mediates LPA-induced potentiation of TRPV1 currents.

It has been demonstrated that Rho, PKC and PKA are downstream molecules of LPA1 [3,31]. Their possible roles in LPA-induced potentiation of TRPV1 currents were determined. In 13 neurons tested, incubation of PKC inhibitor bisindolylmaleimide (BIM, 1 μM, 30 min) blocked potentiation of TRPV1 currents by LPA (Figure 5F, p < 0.05). However, LPA still enhanced TRPV1
Figure 5 PKC, particularly PKCε, but not PKA or Rho, involves in LPA-induced potentiation of TRPV1 currents. Both LPA1 antagonist VPC32183 (1 μM, n = 15, p > 0.05) and PKC inhibitor BIM (1 μM, n = 13, p > 0.05) inhibit potentiation of TRPV1 currents induced by LPA in all of the neurons recorded (A and B). C: After PKA inhibitor H89 (1 μM) was delivered, no effect on LPA-induced potentiation of TRPV1 currents (n = 8, p < 0.001) was observed. D: LPA could still enhance TRPV1 currents in 14 out of 23 neurons tested (p < 0.001) after intracellular delivery of Rho inhibitor BoTXC3 (5 pg/μl). E: Intracellular delivery of PKCε inhibitor εV1-2 (200 μM) completely blocked LPA-induced potentiation of TRPV1 currents (n = 15, p > 0.05). F: Histogram showing summary.
currents in 8 out of 12 neurons after incubation of PKA inhibitor H89 (1 μM, 30 min, Figure 5C, F, \( p < 0.001 \)).

Among the different PKC isoforms, PKCε is co-expressed with TRPV1 in DRG neurons and phosphorylated after inflammation [32]. Translocation of PKCε to the cell membrane triggers TRPV1 phosphorylation and sensitization [24]. Therefore, the present study further determined the role of PKCε in LPA-induced potentiation of TRPV1 current. PKCε inhibitor εV1-2 (200 μM) was delivered intracellularly via a recording electrode 5 min before recording. The potentiation of TRPV1 currents by LPA was completely blocked by εV1-2 in all of the 15 neurons tested (Figure 5E, F, \( p > 0.05 \)), which is consistent with our previous study that PKCε inhibitor blocked substance P-induced potentiation of TRPV1 currents [27].

It is reported that Clostridium botulinum C3 exoenzyme (BoTXC3, a Rho inhibitor by ADP-riboselation) attenuated neuropathic pain at the dose of 10 pg/2 μl [33]. After BoTXC3 (5 pg/μl) was delivered intracellularly, LPA still increased TRPV1 currents in 14 out of 23 neurons (Figure 5D, F, \( p < 0.001 \)), suggesting that Rho may not be an important signal molecule in modulation of TRPV1 by LPA. Similar results were obtained with several different concentrations, from 5 pg/μl to 5 ng/μl (data not shown).

**LPA-induced pain behaviors in bone cancer rats**

To investigate the functional significance of activation of LPA1 in the bone cancer state, LPA1 antagonist VPC32183 was used to examine roles of LPA in bone cancer pain. Bone cancer rats received a lumber puncture of VPC32183 (intrathecal (i.t.), 0.6 mM, 30 μl, \( n = 8 \)) or saline (30 μl, \( n = 8 \)) before cancer cell injection (\( D_9 \)), and \( D_2 \), \( D_4 \), \( D_7 \), \( D_9 \) after cancer cell injection. Ipsilateral paw withdrawal threshold (PWT) to stimuli of von Frey filaments and paw withdrawal latency (PWL) to radiant heating were measured as nociceptive indexes. As shown in Figure 6A, PWTs gradually decreased after injection of cancer cells, exhibiting the development of mechanical allodynia. Administration of VPC32183 significantly attenuated mechanical allodynia for about 5 days. Similarly, VPC32183 significantly attenuated thermal hyperalgesia in bone cancer rats. At \( D_9 \) (\( p < 0.01 \)) and \( D_{11} \) (\( p < 0.01 \)) post-operation, PWLs of the cancer rats that received VPC32183 injection were longer than that of the cancer rats that received saline injection (Figure 6B).

**Discussion**

The transient receptor potential vanilloid subtype 1 (TRPV1) is predominantly expressed in C-fiber nociceptors and responds to capsaicin, noxious heat, protons, and various endogenous ligands [34,35]. Recent studies have revealed that TRPV1 is involved in the development of cancer-induced pain [18-22]. The present study provided further evidence that capsaicin-induced currents and expression of TRPV1 in DRG neurons were up-regulated in bone cancer rats. A line of studies have testified that capsaicin-induced TRPV1 currents in DRG nociceptive neurons are enhanced by different inflammatory mediators such as bradykinin, chemokine and substance P etc. [27,36-39]. LPA was released from diverse sources such as blood platelets, cancer cells and the surrounding tissues. This inflammatory mediator contributed to the initiation of neuropathic pain associated with demyelination in the dorsal root [11]. Our recent studies exhibited that following the development of bone cancer by injection of cancer cells into the tibia, the posterior articular nerve directly innervating the region of bone cancer was severely degraded and the activating transcription factor 3 (ATF3, a marker of nerve injury and stress) expression was up-regulated in DRG neurons at spinal L4-5 segments [40]. Moreover, there was almost no spontaneous firing in the ipsilateral posterior articular nerve of bone cancer (unpublished). Noticeably, the sural nerve innervating the adjacent region of the bone cancer was intensely sensitized [40]. Therefore, capsaicin-induced responses in this study were more likely recorded from uninjured, but not injured, DRG neurons. Considerable evidence has shown that the injured nerve fibers could increase excitability of adjacent uninjured fibers which contributes to the induction of neuropathic pain [41-43]. Given that bone cancer pain characterizes neuropathic pain, it is conceivable that LPA-induced potentiation of TRPV1 current reflects an increase in excitability of uninjured fibers innervating the adjacent region of osteocarcinoma. The facilitation of adjacent uninjured fibers may play a crucial role in the induction of bone cancer pain.

Amongst six subtypes LPA1-6, LPA1 receptors is the main subtype expressed in DRG neurons and activated under the neuropathic pain state [11,15,44]. Consistent with alleviation of neuropathic pain [11], VPC32183, a LPA1 and LPA3 receptors antagonist, blocked LPA-induced potentiation of TRPV1 currents in DRG neurons, mechanical allodynia and thermal hyperalgesia in bone cancer rats, suggesting that activation of LPA1 receptors mediates bone cancer-induced sensitization of DRG nociceptive neurons and pain hypersensitization. A study reported that LPA3 receptors were expressed in some DRG neurons and knockout of LPA3 could relieve pain [45]. Therefore, in addition to LPA1, LPA3 may also contribute to bone cancer pain. The finding that LPA increases intracellular calcium concentration in DRG neurons supports the idea that LPA directly activates DRG neurons via LPA receptors by cross-talking with TRPV1 [46]. The findings that co-localization of
TRPV1 and LPA₁ receptor EDG-2 and bone cancer induced an increase in LPA₁ receptor expression in DRG [40] provide further support for these phenomena. Compelling evidence demonstrates that PKC regulates sensitivity of nociceptors through phosphorylation of many protein substrates [35,37]. Potentiation of TRPV1 currents in DRG neurons by different inflammatory mediators are mediated, at least in part, by PKC [47-51]. It has been known that five isoforms of PKC are expressed in DRG neurons, but only PKCε isoform is translocated to the cell membrane after bradykinin stimulation [52]. Our previous studies showed co-expression of TRPV1 and PKCε and inflammation-induced up-regulation of PKCε in DRG nociceptive neurons [53], and potentiation of TRPV1 currents by activation of Neurokinin 1 (NK-1) receptor via PKCε [27]. As with other G-protein-coupled receptors (GPCR) such as NK-1, LPA₁ receptor activation-induced potentiation of TRPV1 in DRG neurons was also blocked by PKC inhibitor or PKCε inhibitor. In addition to PKC, previous studies demonstrated that PKA inhibitor blocked the potentiation of TRPV1 currents by pro-inflammatory factors such as: NGF, prostaglandins, anandamide, 5-HT, and glutamate [39,46,54-58]. However, the present study revealed that LPA-induced potentiation of TRPV1 failed to be blocked by the PKA inhibitor. Taken together, the interaction of LPA₁ and TRPV1 is mediated by PKC, particularly by PKCε, but not by PKA. The identical process occurs in modulation of TRPV1 by activation of NK-1 in DRG neurons [27]. Therefore, it seems that PKCε, but not PKA, phosphorylation may be a common mechanism in which activation of LPA₁ and NK-1 potentiates TRPV1 in DRG nociceptive neurons contributing to bone cancer pain and neuropathic pain. Interestingly, LPA can increase tetrodotoxin-resistant (TTX-R) sodium current [59] and induce substance P release from nociceptor endings [60]. Our recent finding showed that activation of NK-1 receptor potentiated TTX-R sodium channel Nav1.8 currents, mediated by PKCε in DRG neurons [61]. Collectively, two most important pain-related signal molecules, TRPV1 and Nav1.8, in nociceptors can be modulated by activation of LPA₁ mainly via PKCε phosphorylation.

LPA₁ receptors are reported to interact with members of three major G protein families, G₁₁, G₁₃, and G₁₂ family, to regulate the activity of intracellular messenger molecules [3,62-64]. LPA₁ couples through G₁₂/₁₃ to Rho activation, and inhibition of Rho-associated kinase, a downstream effector of LPA₁, abolished LPA-induced action in osteoblasts [65]. An elegant study from Inoue et al. (2004) reported that Rho-Rho kinase signal pathway is implicated in the induction of neuropathic pain by activation of LPA₁ receptor in DRG neurons. However, the present study showed that inhibition of Rho failed to block LPA-induced potentiation of TRPV1 currents in whole-cell recording of DRG neurons. The different results between the behavioural test and single
cell recording suggest that LPA might be associated with multiple intracellular signals to modulate different targets in DRG neurons. LPA-induced potentiation of TRPV1 currents in DRG neurons is mediated by PKCε rather than Rho pathway. In addition to TRPV1, LPA could modulate other targets in the induction of bone cancer pain, which might be mediated by Rho pathway.

Conclusion
Released by cancer cells and blood platelets, LPA not only promotes cancer cell proliferation but also contributes to the induction of bone cancer pain by enhancing TRPV1 activity in nociceptors. Understanding how cancer cells secrete and recruit cells to release LPA is significant for treatment of cancer pain. Inhibition of the LPA1 receptor or synthesis of LPA may be a novel therapy for cancer pain.

Methods
Animals
Animals used for bone cancer model and all experiments were female Sprague-Dawley (SD) rats weighting 160-200 g. Animals for subculture were female SD rats weighting 80 g. All of them were purchased from the Fudan experimental animal center. All experiments conformed to local and international guidelines on ethical use of animals and all efforts were made to minimize the number of animals used and their sufferings.

Cancer cell inoculation surgery
Walker 256 rat mammary gland carcinoma cells were provided by Fudan University, School of medicine, department of integrative medicine and neurobiology, and were injected into the abdominal cavity of rats weighting 80 g to obtain ascitic fluid for cancer cell culture, continuously cultured from generation to generation weekly for the establishment of a bone cancer model.

Animals were anesthetized with Chloral hydrate (intra-peritoneal (i.p.) 400 mg/kg). The left tibia was chosen as the operated side. 10^7 carcinoma cells in 4 μl phosphate buffered saline (PBS) or 4 μl PBS alone (sham group) were injected into the tibia cavity through the knee joint. The inject site was closed by 1 μl absorbable gelatin sponge. Each animal was injected with 100,000 units of penicillin and had a two days recovery before any experiment. The detailed procedure for cancer cell culture and inoculation has been presented in previous reports [28].

Intrathecal Injection
Rats received intrathecal injection of drugs by lumber puncture as described previously [66]. Briefly, rats were anesthetized with isoflurane in a transparent plastic box and then placed on a roller so that the L4-6 vertebrae were curved. A lumbar puncture needle was introduced into the intrathecal space. The needle had been introduced intrathecally when a short flicking of the tail was observed. Then drugs were slowly injected into the intrathecal space. The needle was immediately pulled out after the injection.

Mechanical allodynia
After 30 min acclimation in an individual testing cage, the rat’s paw withdrawal threshold (PWT) was measured as the hind paw withdrawal response to von Frey hair (Stoelting, IL, USA) stimulation. In detail, an ascending series of von Frey hairs stimuli (2.0, 4.0, 6.0, 8.0, 15.0 and 26.0 g) was applied for 3 s where positive response was defined as a withdrawal of hind paw upon the stimulus, each stimulus was repeated for 5 times with a 10 min interval, and the lowest force to induce at least 3 positive responses was defined as PWT. The tester was blinded to the condition of the animals.

Thermal hyperalgesia
As previously described [67], thermal hyperalgesia was assessed by measuring rat’s paw withdrawal latency (PWL) to a radiant heat (model 336 combination unit, IIITC/life Science Instruments, Woodland Hill, CA, USA). Rats were placed individually in plastic cages on an elevated glass platform and allowed for 30 min acclimation. Each hind paw received three stimuli with a 10 min interval, and the mean of the three withdrawal latencies was defined as PWL. The heat was maintained at a constant intensity. To prevent tissue damage, the cut-off latency was set at 20 s. The tester was blinded to the condition of the animals.

Western-blotting
Animals were anesthetized with Chloral hydrate (i.p. 400 mg/kg). L4,6 DRGs were collected from sham and cancer animals at the 14th day after inoculation surgery, homogenized in a lysis buffer containing protease inhibitor (Sigma, St. Louis, MO, USA). The protein concentrations of each group were measured using a BCA assay (Pierce Biotechnology Inc., Rockford, IL, USA). The extracts were separated using SDS-PAGEs (10%) with 3 mg protein in each lane and transferred to PVDF membranes. The membranes were blocked in 10% non-fat dry milk for 2 h at room temperature (RT). After having been incubated overnight with goat anti-TRPV1 primary antibody (R-18, C-terminal, 1:1,000, Santa Cruz Biotechnology Inc., CA, USA) or mouse anti-Tubulin primary antibody (1:5,000, Sigma), the membranes were incubated with horseradish peroxidase (HRP)-conjugated donkey anti-goat or goat anti-mouse secondary antibody (1:3000, Santa Cruz Biotechnology) for 2 h at RT.
Secondary antibody reactive bands were visualized in ECL solution (Pierce) for 1 min and exposed onto X-films for 1-5 min.

**Immunohistochemistry**

Sensory neurons in L4-6 DRGs of normal rats were labelled by antibodies against TRPV1 and EDG-2 (endothelial differentiation gene-2, LPA1 receptor). Rats were given an overdose of urethane (i.p. 1.5 g/kg) and perfused intracardially with saline, followed by perfusion of 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). L4-6 DRGs were then removed, post-fixed in the same fixative for 4 h at 4°C, and immersed from 10% to 30% gradient sucrose in PB for 24-48 h at 4°C for cryoprotection. Frozen 14 μm DRG sections were cut using a cryostat microtome and thaw-mounted onto gelatin-coated slides for processing. The sections were blocked with 10% donkey serum in 0.01 M PBS (pH 7.4) with 0.3% Triton X-100 for 2 h at RT and incubated for 48 h at 4°C with goat anti-TRPV1 (1:200, Santa Cruz Biotechnology) and rabbit anti-EDG-2 (1:50, Novus Biologicals Inc., CO, USA) primary antibodies in PBS with 1% normal donkey serum and 0.3% Triton X-100. Following three 10 min rinses in 0.01 M PBS, the sections were incubated in rhodamine red-X (RRX)-conjugated donkey anti-goat IgG (1:200, Jackson ImmunoResearch Inc., West Grove, PA, US) and fluorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG (1:200, Jackson Immunonolab) for 90 min at 4°C, and then washed in PBS. All sections were coverslipped with a mixture of 50% glycerin in 0.01 M PBS, and then observed under a Leica fluorescence microscope, and images were captured with a CCD spot camera.

**DRG neurons preparation**

Acutely dissociated DRG neurons were prepared from 180 g rats as described previously [53]. L4-6 DRGs were removed and incubated in Dulbecco’s Modified Eagle Media (DMEM), which was added with 3 mg/ml collagenase (type IA, Sigma) and 1 mg/ml trypsin (type I, Sigma), for 25 min at 36.8°C. After enzyme treatment, ganglia were rinsed three times with standard external solution, and then single cells were dissociated by trituration using fine fire-polished Pasteur pipettes. DRG neurons were placed onto coverslips (10 mm diameter) in the 3.5 cm culture dishes and incubated in Standard external solution for recordings at RT.

**Electrophysiological recordings**

Whole-cell voltage-clamp recordings were made at RT (20-22°C) with an EPC-9 amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany). All recordings were performed within 2-8 h after plating. Neurons were prepared as above. Only small-diameter (15-25 μm) DRG neurons were recorded in all of the experiments. Micro-electrodes were pulled by a P97 puller (Sutter Instruments, Novato, CA, USA) and those with the resistance of 2-6 MΩ were used. Standard external solution contained (in mM): 150 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.4. The pipette solution contained (in mM): 140 KCl, 5 NaCl, 1 MgCl2, 0.5 CaCl2, 5 EGTA, 3 Na2-ATP, and 10 HEPES, pH 7.2. The whole cell capacitance was cancelled and series resistance was compensated (> 80%) after gigahm seal formation and membrane disruption, and data were sampled at 5 kHz and low-passed at 1 kHz. Data acquisition was controlled by the software Pulse and Pulsefit 8.5 (HEKA Elektronik).

**Drugs**

All the drugs for patch-clamp recording and intrathecal injection were purchased from Sigma, except that the LPA1 inhibitor VPC32183 was from Avanti Polar Lipids and PKCe inhibitor εV1-2 was from Biomol (Plymouth Meeting, PA). All the drugs were stocked at -20°C at a concentration of at least 1000-fold the working concentration and prepared on the day of the experiment. LPA and capsaicin were applied close to the neurons by an ALA-VM8 perfusion system (ALA Scientific Instruments, Westbury, NY, USA). Capsaicin was applied once every minute and LPA was applied for 1 min. After cells were washed by standard external solution for 10 seconds, capsaicin was applied for 3 seconds, followed by standard external solution washing for 47 seconds. The control current was averaged from three continuous recordings. In the fourth minute, standard external solution was changed by LPA. Inhibitors were applied (where appropriate) to the chamber 30 min before LPA perfusion, except that BoTXC3 and εV1-2 were delivered intracelluarly via a recording electrode. Inhibitors existed during the whole recording course.

**Statistical analysis**

The western bolt and electrophysiology data were analyzed using student’s t test. Two Way Repeated Measures ANOVA were used to testing differences of PWT and PWL values between groups. The criterion of significance was set at *, # p < 0.05, **, ## p < 0.01, ### p < 0.001, all results are expressed as means ± standard error of the mean (SEM).

**Abbreviations**

LPA: lysophosphatidic acid; TRPV1: transient receptor potential vanilloid; DRG: dorsal root ganglion; CPZ: capsazepine; PKC: protein kinase C; PKA: protein kinase A; MAPK: mitogen-activated protein kinase; EDG-2: endothelial differentiation gene-2 (LPA1 receptor); BIM: bisindolylmaleimide; BOTXC3: Clostridium botulinum C3 exoenzyme; I.T.: intrathecal; PWT: paw withdrawal threshold; PWL: paw withdrawal latency; ATF3: activating transcription factor 3; NK-1: Neurokinin 1; GPCR: G-protein-coupled receptor; TTX-R: tetrodotoxin-
resistant; IP: intra-peritoneal; PBS: phosphate buffered saline; PB: phosphate buffer; RT: room temperature; HRP: horseradish peroxidase; RRX: rhodamine red-X; FITC: fluorescein isothiocyanate; DMEM: Dulbecco's Modified Eagle Media; SEM: standard error of the mean.

Acknowledgements

We thank Ms. Eugenia Hu for editing the manuscript. This work was supported by National Basic Research Program of China Grants 2006CB500807, 2007CB512502, 2007CB512303, Natural Science Fund of China (NSFC) Grants 30830044.

Authors' contributions

HLP performed all of the experiments. YQZ was partially involved in experimental design and guiding. ZQZ is the corresponding author. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 11 May 2010 Accepted: 1 December 2010

Published: 1 December 2010

References

1. Thulliumann B, de Stoutz ND. Causes and treatment of bone pain of malignant origin. Drugs. 1996, 51:383-398.
2. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Luger NM, Mach DR, Schweiz MJ, Sevik MA, Mounty PW: Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 2005, 193:85-100.
3. Antler B, Chun J: Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 2004, 15:457-465.
4. Fang XJ, Schummer M, Mao ML, Yu SX, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaiPurzhin R, Edor A, Jaffe R, Eckison J, Mills GB: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. BBA-Mol Cell Biol 1, 2002, 1582:257-264.
5. Ishihara G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, Gibson SB: Lysophosphatidic acid (LPA) protected cancer cells from histone deacetylase inhibition (HDAC) Inhibitor-induced apoptosis through activation of HDAC. J Biol Chem 2008, 283:16818-16829.
6. Radde-F Huang J, Seelos TM, Matteo RG, Brown JH: G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004, 92:949-966.
7. Guo R, Kabbohm EA, Arao P, Sample C, Baban B, Sud N, Sivashanmugam P, Monir NH, Daaka Y: Expression and function of lysophosphatidic acid LPA(1) receptor in prostate cancer cells. Endocrinology 2006, 147:4883-4892.
8. Aoki J, Taara A, Takanearava Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arari H: Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002, 277:4837-4844.
9. Bouchabara A, Serre CM, Gres S, Sauvall-Blaché JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O: Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastasis in breast cancer. J Clin Invest 2004, 114:1714-1725.
10. Eder AM, Sasaegawa T, Mao M, Aoki J, Mills GB: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000, 6:2482-2491.
11. Inoue M, Rashid MH, Fujita R, Contos JJA, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10:712-718.
12. Inoue M, Yamaguchi A, Kawamori M, Chun J, Ueda H: Loss of spinal substance P transmission under the condition of LPA-receptor-mediated neuropathic pain. Mol Pain 2006, 2:25.
13. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G(12/13) and G(q)-coupled lysophosphatidic acid receptor that increases cAMP, LPA(1). J Biol Chem 2006, 281:23589-23597.
14. Noguchi K, Ikidi S, Shimizu T: Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003, 278:25600-25606.
15. Ahn DK, Lee SY, Han SR, Ju JS, Yang GY, Lee MK, Youn DH, Bae YC. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 2009, 146:114-120.
16. Fujita R, Kiguchi N, Ueda H: LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 2007, 50:351-355.
17. Tominaga M, Caterina MJ: Thermosensation and pain. J Neurosci 2004, 61:3-12.
18. Higashiro JR, Röhrich H, Lindsay TH, Sevik MA, Schweiz MJ, Kubota K, Halvorsen KG, Pobje J, Chapman SR, Dubin AE, Canfield NJ, Saunders E, Kuskovsky M, Flores CM, Julius D, Mantyh PW: Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005, 25(12):3136-3141.
19. Honore P, Chandran P, Fernandez G, Gauvin DP, Mikusa J, Zhong C, Joshi SK, Higashiro JR, Sevik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daenae JF, Gomtans A, Lee CH, Kore MT, Reilly RM, Sunwoo CS, Kym PA, Mantyh PW, Sullivan JP, Jarvis MF, Fatynec CR. Repeated dosing of A87-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009, 142:27-35.
20. Menéndez L, Juárez L, García E, García-Suárez O, Hidalgo A, Raamonde A: Analgesic effects of capsaicin and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006, 393:70-73.
21. Niwayama N, Kawamata T, Yamamoto J, Omote K, Nakami K: Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 2007, 148:560-572.
22. Niwayama N, Yamamoto T, Yamamoto J, Furuse S, Nakami K. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Brit J Anaesth 2009, 102(2):251-258.
23. Adcock JJ, TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009, 22:65-70.
24. Numazaki M, Tominaga T, Toyooka H, Tominaga M: Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsin and identification of two target serine residues. J Biol Chem 2002, 277:13375-13378.
25. van der Stelt M, Di Marzo V: Endovanilloids – Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004, 271:1827-1834.
26. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21:531-543.
27. Zhang H, Cang C, Kawasaki Y, Liang LL, Zhao ZQ, Ji RR, Zhao ZQ. Neurokinin-1 receptor enhances TRPV1 activity in primary sensory neurons via PKCepsin: a novel pathway for heat hyperalgesia. J Neurosci 2007, 27:12067-12077.
28. Mao-Ying QL, Zhao J, Dong QZ, Wang J, Yu J, Yan MF, Zhang YQ, Wu GC, Wang YQ, A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun 2006, 345:1292-1298.
29. Schweiz MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Chohsy DR, Mantyh PW: Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999, 19:10886-10897.
30. Mantyh PW: A mechanism-based understanding of bone cancer pain. Novartis Foundation symposium 2004, 261:194-214.
31. Fukushima N, Chun J. The LPA receptors. Prostag Other Lipid Mediat 2001, 64:21-32.
32. Zhou Y, Li GD, Zhao QZ. State-dependent phosphorylation of epsilon-isozyme of protein kinase C in adult rat dorsal root ganglia after inflammation and nerve injury. J Neurochem 2003, 85:571-580.
33. Ye X, Inoue H, Ueda H. Botulinum toxin C3 inhibits hyperalgesia in mice with partial sciatic nerve injury. Jpn J Pharmacol 2003, 83:161-163.
34. Caterina MJ, Schumacher MA, Tomingana M, Rose TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
35. Nagy I, Santpa Z, Jancso G, Urban L: The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004, 500:351-369.
36. Cesare P, McNaughton P: A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc Natl Acad Sci USA 1996, 93:15435-15439.
37. Ferreira J, da Silva GL, Calixto JB. Contribution of vanilloid receptors to the overt noiception induced by B-2 kinin receptor activation in mice. British Journal of Pharmacology 2004, 141:787-794.
38. Shu X, Mendell LM. Acute sensitization by NGF of the response of small-diameter sensory neurons to capsaicin. J Neurophysiol 2001, 88:2931-2938.
39. Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ. A proinflammatory chemokine, CCL3, sensitizes the heat-and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci USA 2005, 102:4536-4541.
40. Zhao J, Pan HL, Li TT, Zhang YQ, Zhao ZQ. The sensitization of peripheral C-fibers to lysophosphatidic acid in bone cancer pain. Life Sci 2010, 87:120-125.
41. Ali Z, Ringkamp M, Harte TV, Chen HF, Flavahan NA, Campbell JN, Meyer RA. Uninjured C-fiber nociceptors develop spontaneous activity and alpha-adrenergic sensitivity following L6 spinal nerve ligation in monkey. J Neurophysiol 1999, 81:455-466.
42. Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci 2006, 26:1281-1292.
43. Wu G, Ringkamp M, Harte TV, Murinson B8, Campbell JN, Griffin JW, Meyer RA. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci 2001, 21:1-5, RC140.
44. Ma L, Matsumoto M, Xie WJ, Inoue M, Ueda H. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem 2009, 109:603-610
45. Ma L, Uchida H, Nagai J, Inoue M, Chun J, Aoki J, Ueda H. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol Pain 2009, 5:64.
46. Elmes SJ, Miltinis PJ, Smart D, Kendall DA, Chapman V. Evidence for biological effects of exogenous LPA on rat primary afferent and spinal cord neurons. Brain Res 2004, 1022:205-213.
47. Obreja O, Rathee PK, Lip S, Distler C, Kress M. IL-10 potentiates heat-activated currents in rat sensory neurons: involvement of IL-1R1, tyrosine kinase, and protein kinase C. Faseb Journal 2002, 16:1497-1503.
48. Sugiuara T, Tominaga M, Katsuya H, Mizumura K. Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor. J Neurophysiol 2002, 88:544-548.
49. Aramides S, Nie JJ, Vergnolle N, Cottrell GS, Grady EF, Trevisani M Manni C, Geppetti P, McRoberts JA, Ennes H, Davis B, Mayer EA, Burnett NW: Protease-activated receptor 2 sensitizes the capsacin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004, 24:4303-4312.
50. Carlton SA, Zhou ST, Du JH, Hargett GL, Ji GC, Gogoshal RE. Somatostatin modulates the transient receptor potential vanilloid 1 (TRPV1) ion channel. Pain 2004, 110:616-627.
51. Dai Y, Monyama T, Higashi T, Togashi K, Kobayashi K, Yamanaoka H, Tominaga M, Noguchi K. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. J Neurosci 2004, 24:4293-4299.
52. Cesare P, Dekker LV, Sardini A, Parker PJ, McNaughton PA. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999, 23:617-624.
53. Zhou Y, Zhou ZS, Zhao ZQ. PKC regulates capsaicin-induced currents of dorsal root ganglion neurons in rats. Neuropharmacology 2001, 41:601-608.
54. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW: cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002, 35:721-731.
55. Monyama T, Higashi T, Togashi K, Iida T, Sugi T, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1:3.
56. Hucho TB, Dina OA, Levine JD. Epac mediates a cAMP-to-PKC signaling in inflammatory pain: an isolectin B4(+) neuron-specific mechanism. J Neurosci 2005, 25:6119-6126.
57. Rathee PK, Distler C, Obreja O, Neuhuber W, Wang G, Wang SY, Nau C, Kress M. PKA/ACK/VR-1 module: A common link of G(s)-mediated signaling to thermal hyperalgesia. J Neurosci 2002, 22:4740-4745.